Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.

about

Tissue-based biomarkers in prostate cancer.Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.

P2860

Q47144748-AAC0C4CA-5DD0-4908-8874-2A39941E8389 Q55340786-0AF0CA41-7CCF-45DB-BCC6-AC290299F35C

P2860

Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.

Item

http://www.wikidata.org/entity/Q38375214

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Prospective Validation of Diag ...... iotherapy for Prostate Cancer.

@en

type

Item

label

Prospective Validation of Diag ...... iotherapy for Prostate Cancer.

@en

prefLabel

Prospective Validation of Diag ...... iotherapy for Prostate Cancer.

@en

P1476

Prospective Validation of Diag ...... iotherapy for Prostate Cancer.

@en

P2093

Alan Pollack

http://www.w3.org/2001/XMLSchema#string

Deukwoo Kwon

http://www.w3.org/2001/XMLSchema#string

Eric M Horwitz

http://www.w3.org/2001/XMLSchema#string

Gail Walker

http://www.w3.org/2001/XMLSchema#string

Li Yan Khor

http://www.w3.org/2001/XMLSchema#string

Mark K Buyyounouski

http://www.w3.org/2001/XMLSchema#string

Radka Stoyanova

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.

Concordance for prognostic models with competing risks

BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.

The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.

Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJW232

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28376214

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

biomarker

P932

6075027

http://www.w3.org/2001/XMLSchema#string

Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.

about

P2860

P2860

Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932